Viewing Study NCT06232005



Ignite Creation Date: 2024-05-06 @ 8:02 PM
Last Modification Date: 2024-10-26 @ 3:19 PM
Study NCT ID: NCT06232005
Status: COMPLETED
Last Update Posted: 2024-01-30
First Post: 2024-01-22

Brief Title: Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture
Sponsor: Ain Shams University
Organization: Ain Shams University

Study Overview

Official Title: Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture
Status: COMPLETED
Status Verified Date: 2024-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To evaluate the effectiveness of administering mitomycin C through intralesional injection after performing visual internal urethrotomy VIU for the treatment of recurring urethral stricture
Detailed Description: Numerous studies have investigated the impact of intralesional administration of antifibrotic drugs on urethral strictures following visual internal urethrotomy VIU These drugs include mitomycin C botulinum toxin A somatostatin analog and glucocorticoids Mitomycin C MMC is known for its potent chemotherapeutic and antibiotic properties It effectively hinders mitosis and fibroblast proliferation playing a crucial role in tissue healing and scar formation by reducing the release of matrix proteins through the inhibition of proliferative fibroblasts With its anti-proliferative and anti-scarring characteristics MMC proves to be a suitable option for treating recurrent urethral strictures

thus we conduct a randomized controlled trial to evaluate the safety and efficacy of Mitomycin in decrease urethral stricture recurrence

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None